A phase I clinical trial of the DNA vaccine for Middle East respiratory syndrome (INO-4500) in healthy volunteers

Trial Profile

A phase I clinical trial of the DNA vaccine for Middle East respiratory syndrome (INO-4500) in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs INO 4500 (Primary)
  • Indications Coronavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GeneOne Life Science
  • Most Recent Events

    • 04 Jun 2015 New trial record
    • 27 May 2015 According to an Inovio media release, the company plans to initiate this study before the end of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top